A drug which has been used for decades to treat high blood pressure may turn out to be a key treatment for multiple sclerosis, say British researchers.
England's public-health watchdog group has recommended that their drug Tysabri be used to treat a debilitating form of multiple sclerosis.
Savitex, an oral spray developed by the drugs company GW Pharmaceuticals, is now unlikely to gain regulatory approval in this country until 2009 despite recently winning full regulatory approval in Canada
A lack of funding has forced a Cardiff-based MS service to start a waiting list for patients who could benefit from beta interferon and copaxone.
"I have had MS for 25 years and although I have remained fairly stable I find that I am prone to periods of depression."
European Journal of Neurology (EJN) reports a study1 which shows that Sativex, a cannabis based medicine, significantly reduces intractable spasms and stiffness (spasticity) in people with Multiple Sclerosis
A couple who gave thousands of chocolate bars laced with cannabis to multiple sclerosis patients for pain relief were found guilty yesterday of conspiring to supply the drug.
The MS Society is 'bitterly disappointed' after the Scottish Medicines Consortium (SMC) advised health professionals not to prescribe Tysabri - the only drug licensed for multiple sclerosis (MS) that has shown significant promise in slowing the progress
A three-year controlled study is being launched at 10 centers across the United Kingdom to further investigate the potential of the drug combination. The results of the initial trial, led by Dr. Mike Boggild at the Walton Centre in Liverpool, will be publ
The United Kingdom early Mitoxantrone Copaxone trial is a controlled study which will compare combination therapy with mitoxantrone and Glatiramer Acetate (Copaxone) against high dose interferon beta treatment (Rebif 44).
Doctors at Walton began treating patients with a combination of a chemotherapy drug normally used to treat cancer called mitoxantrone, with an MS anti-relapse drug Copaxone, in 2001.
GW pharmaceuticals is developing a portfolio of cannabis medicines the first of which, Sativex, received an Approval with Conditions from Health Canada in April 2005 for use as an adjunctive treatment for the symptom relief of neuropathic pain in MS
Information on sativex: news, experiences and updates
THC4MS aims to supply medicinal cannabis chocolate information to bone-fide MS sufferers i.e. As a first point of contact.
Prosecutors are taking a firm line on the supply of cannabis for pain relief to people with chronically painful conditions such as multiple sclerosis, despite the downgrading of the drug from class B to class C.
